The FDA Just Set a Lung Cancer Survival Bar That No Approved Drug Has Cleared
The FDA rejected ivonescimab after its global trial missed the statistical bar on overall survival, a benefit no approved regimen in this lung cancer setting has shown, though the drug's China trial did.












